A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors Conditions: Pediatric Solid Tumor; Refractory Tumor; Recurrent Tumor; CNS Malignancies Intervention: Drug: Ramucirumab
Principal Investigator:
Josephine HaDuong, MD
Research Coordinator:
Tina Templeman
(714) 509-8646
Visit clinicaltrials.gov for more information about this trial.
- IRB Number: 151189
- Sponsor: COG
- Protocol Number: ADVL1416
- NCT Number: NCT02564198
- Research Type: Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors
- Phase: I
- Status: Active
Key Inclusion Criteria:
- Age:12 Months to 21 Years
- Part A: participants with recurrent or refractory non-CNS solid tumors
- Part B: participants with recurrent or refractory CNS tumors
Key Exclusion Criteria:
- Standard COG Phase 1 organ function requirements
- Active or recent history of serious bleeding events
- Active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
- Active or recent history of hypertensive crisis or hypertensive encephalopathyActive non-healing wound or bone fractureHistory of solid organ transplant
